Drug Use Evaluation of Mood Stabilisers in Outpatients with Bipolar Disorder at a Psychiatric Hospital in Padang City
Main Article Content
Page: 2601-2608
Abstract
Bipolar disorder is a chronic psychiatric condition that requires long-term pharmacotherapy to control symptoms and prevent relapse. Mood stabilisers play a central role in its management; however, inappropriate use may reduce treatment effectiveness and increase the risk of adverse outcomes. This study aimed to evaluate the appropriateness of mood stabiliser use among outpatients with bipolar disorder at a psychiatric hospital in Padang City. This retrospective descriptive study used medical record data from January to December 2023. A total of 28 patients who met the inclusion criteria were included, with 220 outpatient visits analysed. Data collected included sociodemographic characteristics, clinical conditions, and medication use. The appropriateness of therapy was assessed based on four criteria: indication, patient suitability, drug selection, and dosage, using established pharmacotherapy guidelines as the reference standard. The results showed that most patients were female (78.57%) and aged 18–59 years (75%). The evaluation of drug use demonstrated that the appropriateness of indication, patient suitability, and drug selection each reached 83.18%. However, dosage appropriateness was considerably lower at 54.55%, indicating that nearly half of the prescriptions involved suboptimal dosing. While most aspects of mood stabiliser use were generally appropriate, dosing remains a critical issue that may affect treatment effectiveness and patient safety. These findings highlight the importance of improving adherence to clinical guidelines and conducting regular evaluations of pharmacotherapy to optimise outcomes in patients with bipolar disorder.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Voelker R. (2024). What Is Bipolar Disorder?. JAMA, 331(10), 894. https://doi.org/10.1001/jama.2023.24844 DOI: https://doi.org/10.1001/jama.2023.24844
Ferrari, A. J., Stockings, E., Khoo, J. P., Erskine, H. E., Degenhardt, L., Vos, T., & Whiteford, H. A. (2016). The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disorders, 18(5), 440–450. https://doi.org/10.1111/bdi.12423 DOI: https://doi.org/10.1111/bdi.12423
Beyer, J. L., & Weisler, R. H. (2016). Suicide Behaviours in Bipolar Disorder: A Review and Update for the Clinician. The Psychiatric Clinics of North America, 39(1), 111–123. https://doi.org/10.1016/j.psc.2015.09.002 DOI: https://doi.org/10.1016/j.psc.2015.09.002
World Health Organisation. (2023). Bipolar disorder. https://www.who.int/news-room/fact-sheets/detail/bipolar-disorder
Rowland, T. A., & Marwaha, S. (2018). Epidemiology and risk factors for bipolar disorder. Therapeutic advances in psychopharmacology, 8(9), 251–269. https://doi.org/10.1177/2045125318769235 DOI: https://doi.org/10.1177/2045125318769235
Ministry of Health of the Republic of Indonesia. (2018). Basic Health Research (Riskesdas) 2018. Jakarta: Ministry of Health of the Republic of Indonesia
Munira, L., Liamputtong, P., & Viwattanakulvanid, P. (2023). Barriers and facilitators to access mental health services among people with mental disorders in Indonesia: A qualitative study. Belitung Nursing Journal, 9(2), 110–117. https://doi.org/10.33546/bnj.2521 DOI: https://doi.org/10.33546/bnj.2521
Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. Lancet (London, England), 381(9878), 1672–1682. https://doi.org/10.1016/S0140-6736(13)60857-0 DOI: https://doi.org/10.1016/S0140-6736(13)60857-0
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O'Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., McIntyre, R. S., … Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609 DOI: https://doi.org/10.1111/bdi.12609
Gitlin M. (2016). Lithium side effects and toxicity: prevalence and management strategies. International journal of bipolar disorders, 4(1), 27. https://doi.org/10.1186/s40345-016-0068-y DOI: https://doi.org/10.1186/s40345-016-0068-y
Perucca E. (2002). Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs, 16(10), 695–714. https://doi.org/10.2165/00023210-200216100-00004 DOI: https://doi.org/10.2165/00023210-200216100-00004
Spina, E., Pisani, F., & Perucca, E. (1996). Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clinical Pharmacokinetics, 31(3), 198–214. https://doi.org/10.2165/00003088-199631030-00004 DOI: https://doi.org/10.2165/00003088-199631030-00004
American Society of Health-System Pharmacists. (2021). ASHP guidelines on medication-use evaluation. American Journal of Health-System Pharmacy, 78(4), 341–352
World Health Organisation. (2019). Promoting rational use of medicines: Core components. Geneva: World Health Organisation.
Diflorio, A., & Jones, I. (2010). Is sex important? Gender differences in bipolar disorder. International review of psychiatry (Abingdon, England), 22(5), 437–452. https://doi.org/10.3109/09540261.2010.514601 DOI: https://doi.org/10.3109/09540261.2010.514601
Albert P. R. (2015). Why is depression more prevalent in women?. Journal of psychiatry & neuroscience: JPN, 40(4), 219–221. https://doi.org/10.1503/jpn.150205 DOI: https://doi.org/10.1503/jpn.150205
Rifaya A, Agustina R, Rusli R. Pola Penggunaan Obat Mood Stabilizer Pada Pasien Bipolar di Rumah Sakit Jiwa Daerah Atma Husada Mahakam. Proc Mul Pharm Conf. 2019;10:86–93 DOI: https://doi.org/10.25026/mpc.v10i1.368
Anggraeni MD, Agustina R, Indriyanti N. Pola Penggunaan Obat Antikonvulsan pada Pasien Gangguan Kejiwaan di Rumah Sakit Jiwa Daerah Atma Husada Mahakam Samarinda. Proc Mul Pharm Conf. 2019;10:48–51 DOI: https://doi.org/10.25026/mpc.v10i1.345
Solmi, M., Radua, J., Olivola, M., Croce, E., Soardo, L., Salazar de Pablo, G., Il Shin, J., Kirkbride, J. B., Jones, P., Kim, J. H., Kim, J. Y., Carvalho, A. F., Seeman, M. V., Correll, C. U., & Fusar-Poli, P. (2022). Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Molecular Psychiatry, 27(1), 281–295. https://doi.org/10.1038/s41380-021-01161-7 DOI: https://doi.org/10.1038/s41380-021-01161-7
Marwaha, S., Durrani, A., & Singh, S. (2013). Employment outcomes in people with bipolar disorder: a systematic review. Acta Psychiatrica Scandinavica, 128(3), 179–193. https://doi.org/10.1111/acps.12087 DOI: https://doi.org/10.1111/acps.12087
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., Singh, A. B., & Murray, G. (2021). The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. The Australian and New Zealand journal of psychiatry, 55(1), 7–117. https://doi.org/10.1177/0004867420979353 DOI: https://doi.org/10.1177/0004867420979353
Grover, S., Avasthi, A., Sinha, V., Lakdawala, B., Bathla, M., Sethi, S., Mathur, D. M., Kathuria, P., Shah, S., Baalasubramanian, D. S., Agarwal, V., & Deka, K. (2014). Indian Psychiatric Society multicentric study: Prescription patterns of psychotropics in India. Indian journal of psychiatry, 56(3), 253–264. https://doi.org/10.4103/0019-5545.140632 DOI: https://doi.org/10.4103/0019-5545.140632
Kadra, G., Stewart, R., Shetty, H., MacCabe, J. H., Chang, C. K., Kesserwani, J., Taylor, D., & Hayes, R. D. (2018). Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology, 235(1), 281–289. https://doi.org/10.1007/s00213-017-4767-6 DOI: https://doi.org/10.1007/s00213-017-4767-6
Goodwin, G. M., Haddad, P. M., Ferrier, I. N., Aronson, J. K., Barnes, T., Cipriani, A., Coghill, D. R., Fazel, S., Geddes, J. R., Grunze, H., Holmes, E. A., Howes, O., Hudson, S., Hunt, N., Jones, I., Macmillan, I. C., McAllister-Williams, H., Miklowitz, D. R., Morriss, R., Munafò, M., … Young, A. H. (2016). Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England), 30(6), 495–553. https://doi.org/10.1177/0269881116636545 DOI: https://doi.org/10.1177/0269881116636545
National Institute for Health and Care Excellence. (2020). Bipolar disorder: Assessment and management (NICE guideline CG185). London: NICE
McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., Vieta, E., Vinberg, M., Young, A. H., & Mansur, R. B. (2020). Bipolar disorders. Lancet (London, England), 396(10265), 1841–1856. https://doi.org/10.1016/S0140-6736(20)31544-0 DOI: https://doi.org/10.1016/S0140-6736(20)31544-0
American Society of Health-System Pharmacists. (2021). ASHP guidelines on medication-use evaluation. American Journal of Health-System Pharmacy, 78(4), 341–352